Allison King is an Oncology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Childrens Pl
Div Ped Hematology And Onc
Saint Louis, MO 631101002
Telephone
314-454-6018Registry record last updated 17 Apr 2025.
Clinical trials
- Increasing Optimal Use of HPV Vaccination in Primary Care
Sponsor: Washington University School of Medicine
- A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study
Sponsor: Washington University School of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Sun Pharmaceutical Industries Inc.Program year20234 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
59.2%Opioid Agonist50.8%Oxycodone Hcl100%Part D<11 patientsGabapentinoids8.5%Gabapentin100%Part D<11 patientsAnti-infectives
11.5%Penicillin-class Antibacterial11.5%Penicillin V Potassium100%Part D<11 patientsRespiratory
10%Corticosteroid10%Fluticasone Propionate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2006–2026 per NIH RePORTER. The latest:
- (SCANS) Sickle Cell Anemia Neurodevelopmental Screening - Mentoring and Research in Patient Oriented Research
Washington University
FY2026$144,845K24HL148305 - RCT to Evaluate an Implementation Strategy to Increase Optimal Use of HPV Vaccine in Primary Care
Washington University
FY2024$467,069R01CA235615 - (SCANS) Sickle Cell Anemia Neurodevelopmental Screening - Mentoring and Research in Patient Oriented Research
Washington University
FY2023$109,455K24HL148305
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”